Oppenheimer Assumes Cue Biopharma at Outperform, Announces Price Target of $10
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach assumes Cue Biopharma (NASDAQ:CUE) with an Outperform rating and announces a price target of $10.
June 26, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Mark Breidenbach assumes Cue Biopharma with an Outperform rating and sets a price target of $10.
The Outperform rating and price target announcement by Oppenheimer analyst Mark Breidenbach is likely to have a positive short-term impact on Cue Biopharma's stock price. Investors may see this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100